Purpose
This open-label phase III trial evaluated efficacy and tolerability of linifanib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy.Patients and methods
Patients were randomly assigned in a 1:1 ratio to linifanib 17.5 mg o...
